| Highly stable Si− C linked functionalized monolayers on the silicon (100) surface AB Sieval, AL Demirel, JWM Nissink, MR Linford, JH Van der Maas, ... Langmuir 14 (7), 1759-1768, 1998 | 703* | 1998 |
| Seven Year Itch: Pan-Assay Interference Compounds (PAINS) in 2017 Utility and Limitations JB Baell, JWM Nissink ACS chemical biology 13 (1), 36-44, 2018 | 615 | 2018 |
| A new test set for validating predictions of protein–ligand interaction JWM Nissink, C Murray, M Hartshorn, ML Verdonk, JC Cole, R Taylor Proteins: structure, function, and bioinformatics 49 (4), 457-471, 2002 | 552 | 2002 |
| Modeling water molecules in protein− ligand docking using GOLD ML Verdonk, G Chessari, JC Cole, MJ Hartshorn, CW Murray, ... Journal of medicinal chemistry 48 (20), 6504-6515, 2005 | 489 | 2005 |
| Comparing protein–ligand docking programs is difficult JC Cole, CW Murray, JWM Nissink, RD Taylor, R Taylor Proteins: Structure, Function, and Bioinformatics 60 (3), 325-332, 2005 | 441 | 2005 |
| PAINS in the assay: chemical mechanisms of assay interference and promiscuous enzymatic inhibition observed during a sulfhydryl-scavenging HTS JL Dahlin, JWM Nissink, JM Strasser, S Francis, LA Higgins, H Zhou, ... Journal of medicinal chemistry 58 (5), 2091-2113, 2015 | 386 | 2015 |
| Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent KM Foote, JWM Nissink, T McGuire, P Turner, S Guichard, JWT Yates, ... Journal of medicinal chemistry 61 (22), 9889-9907, 2018 | 264 | 2018 |
| Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): A Potent and Selective Inhibitor of ATR Protein … KM Foote, K Blades, A Cronin, S Fillery, SS Guichard, L Hassall, I Hickson, ... Journal of medicinal chemistry 56 (5), 2125-2138, 2013 | 257 | 2013 |
| Virtual screening in drug discovery J Alvarez, B Shoichet CRC press, 2005 | 195 | 2005 |
| Potent and selective inhibitors of MTH1 probe its role in cancer cell survival JG Kettle, H Alwan, M Bista, J Breed, NL Davies, K Eckersley, S Fillery, ... Journal of medicinal chemistry 59 (6), 2346-2361, 2016 | 162 | 2016 |
| Simple size-independent measure of ligand efficiency JWM Nissink Journal of chemical information and modeling 49 (6), 1617-1622, 2009 | 120 | 2009 |
| Protein-ligand docking and virtual screening with GOLD JC Cole, JWM Nissink, R Taylor Virtual screening in drug discovery 1, 379-415, 2005 | 120 | 2005 |
| Promiscuous 2-aminothiazoles (PrATs): a frequent hitting scaffold SM Devine, MD Mulcair, CO Debono, EWW Leung, JWM Nissink, SS Lim, ... Journal of medicinal chemistry 58 (3), 1205-1214, 2015 | 98 | 2015 |
| Discovery of AZD9833, a potent and orally bioavailable selective estrogen receptor degrader and antagonist JS Scott, TA Moss, A Balazs, B Barlaam, J Breed, RJ Carbajo, ... Journal of medicinal chemistry 63 (23), 14530-14559, 2020 | 90 | 2020 |
| (Thio) urea resorcinarene cavitands. Complexation and membrane transport of halide anions H Boerrigter, L Grave, JWM Nissink, LAJ Chrisstoffels, JH van der Maas, ... The Journal of Organic Chemistry 63 (13), 4174-4180, 1998 | 85 | 1998 |
| Mimicry by asx‐and ST‐turns of the four main types of β‐turn in proteins WJ Duddy, JWM Nissink, FH Allen, EJ Milner‐White Protein Science 13 (11), 3051-3055, 2004 | 75 | 2004 |
| Cellularly active N-hydroxyurea FEN1 inhibitors block substrate entry to the active site JC Exell, MJ Thompson, LD Finger, SJ Shaw, J Debreczeni, TA Ward, ... Nature chemical biology 12 (10), 815-821, 2016 | 73 | 2016 |
| Quantification of frequent-hitter behavior based on historical high-throughput screening data JWM Nissink, S Blackburn Future Medicinal Chemistry 6 (10), 1113-1126, 2014 | 63 | 2014 |
| Structures of the human poly (ADP-ribose) glycohydrolase catalytic domain confirm catalytic mechanism and explain inhibition by ADP-HPD derivatives JA Tucker, N Bennett, C Brassington, ST Durant, G Hassall, G Holdgate, ... PloS one 7 (12), e50889, 2012 | 62 | 2012 |
| Increasing the delivery of next generation therapeutics from high throughput screening libraries MJ Wigglesworth, DC Murray, CJ Blackett, M Kossenjans, JWM Nissink Current Opinion in Chemical Biology 26, 104-110, 2015 | 55 | 2015 |
Jason ColeDeputy Director, CCDC確認したメール アドレス: ccdc.cam.ac.uk
